Genetic Risks to the Mother and the Infant: Assessment, Counseling, and Management by unknown
Matern Child Health J (2006) 10:S143–S146
DOI 10.1007/s10995-006-0099-6
Genetic Risks to the Mother and the Infant:
Assessment, Counseling, and Management
Stuart K. Shapira · Siobhan Dolan
Published online: 20 June 2006
C© Springer Science+Business Media, Inc. 2006
Key Words Prenatal genetic risks . Family history
assessment . Advanced maternal age . Advanced paternal
age . Preconception genetic counseling . Pregnancy risks
from genetic conditions
In order to optimize the chance for a healthy pregnancy
and baby, a woman’s risk factors related to a variety of
health issues (diet, medications, and exposures) are gen-
erally examined, allowing for required modifications dur-
ing preconception care [1]. This activity can help prevent
some birth defects and some adverse birth outcomes, such
as prematurity. In contrast, genetic factors result in con-
ditions often perceived to be rare, and thus most women
without a family history of birth defects or genetic condi-
tions do not consider themselves at risk. Regardless, a full
range of genetic issues should always be considered pre-
conceptionally to improve the chance for a healthy birth
outcome.
Preconception care involves genetics in two distinct man-
ners: 1) the assessment of risk factors for having a child with
a genetic disorder and providing information about precon-
ception and prenatal testing, as well a reproductive options
to minimize the chance of having genetic problems in future
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children; and 2) the care of women with genetic disorders
preconceptionally and during pregnancy.
Very few studies have evaluated the extent of genetic is-
sues that are currently addressed in preconceptional care
venues since genetic concerns often do not become impor-
tant to a woman and/or her healthcare providers until she
is pregnant. The most comprehensive examination of repro-
ductive health occurs in the Hungarian periconceptual health
care service, which has 20 years of experience in protecting
the health of potential mothers through pregnancy, reducing
the occurrence of unsuccessful pregnancy outcomes (includ-
ing birth defects and genetic diseases), and promoting the
birth of healthy infants [2, 3]. Through this service, couples
undergo comprehensive health screening, family history as-
sessment, referral for carrier screening for cystic fibrosis,
and predictive genetic testing based on family history, when
appropriate. Unlike the Hungarian experience, there has not
been a concerted approach toward genetic risk assessment
during the preconception period in the United States because
the first visit for medical care is usually an antenatal visit in
the 6–12th week of gestation. Therefore, standards need to be
developed for the incorporation of genetic risk assessments
and counseling into a preconception care program.
Preconception genetic care should focus on providing an
understanding of risk–specifically, assessing the risks and
communicating appropriate information via non-directive
counseling about birth defects and genetic disorders that
may occur during a pregnancy. All couples have a baseline
population risk of having an infant with a major birth defect
or genetic problem. This empirical risk is 2–5%, and is based
on population data [4–6]. This conglomerate risk for any of
the full spectrum of birth defects, chromosomal abnormali-
ties, and single gene disorders does not take into account the
individualized risks for a woman’s future pregnancy, such
as those based on familial factors, ethnic background, and
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parental age, all of which may increase the risk to one above
the population risk. Given the reality of the general and the
specific risks for each woman, a thorough individualized risk
assessment and the provision of appropriate genetic counsel-
ing information are necessary for a couple to understand their
genetic risks for a pregnancy.
A family history assessment, often performed by a ge-
netic counselor, genetic nurse, or clinical geneticist, is used
to determine familial factors that may increase the risk for
genetic problems in a future pregnancy. Unfortunately, most
women do not receive medical services from such health-
care providers unless there is a known or suspected genetic
problem in the family. Therefore, self-assessment tools have
been developed for obtaining a family history and alerting
women who, based on increased risk factors determined by
the assessment tool, should seek further genetic counseling
[7–11]. Familial risk factors can include a family history
of single gene disorders such as muscular dystrophy, cystic
fibrosis, sickle cell disease, and Fragile X syndrome [12,
13], chromosomal abnormalities, unexplained mental retar-
dation, multiple miscarriages, and major birth defects. Any
increase above the baseline population risk would depend
upon the precise condition in the family, the inheritance pat-
tern, and the degree of relatedness to the woman or her
partner. For familial conditions that are the result of muta-
tions in single genes or inheritance of unbalanced chromo-
somal constitutions from carriers of balanced chromosomal
rearrangements, preconception care should include offering
genetic testing to determine if the woman and/or her part-
ner is a carrier for the condition, which might substantially
increase the genetic risk for a future pregnancy. Numerous
advantages derive from discussing these risks and perform-
ing appropriate testing in the preconception period rather
than during a pregnancy. These include 1) having adequate
time available to obtain test results from those with long turn-
around times and to obtain follow-up testing, if required, 2)
not being limited by gestational age for the performance of
specific prenatal diagnostic options, and 3) allowing discus-
sions of reproductive planning to occur without the concern
about the outcome of an ongoing pregnancy.
An ethnic background assessment is also part of a de-
tailed family history, since certain genetic conditions are
more prevalent in individuals of particular backgrounds. For
example, individuals of Ashkenazi Jewish ancestry should
be informed of their possible increased risk to have an infant
with conditions such as Tay-Sachs disease, cystic fibrosis,
Gaucher disease, and several other conditions [14]. Cau-
casians, particularly those of northern European ancestry,
should be informed about a possible increased risk of cystic
fibrosis [15]. African-Americans should be informed about
the risk of sickle cell disease [16]. Finally, individuals of
Mediterranean ancestry should be informed about the risk of
thalassemia in an infant [16]. For a woman who is at higher
risk for having children with these and/or other conditions,
genetic testing is appropriate to determine if she is a carrier
for the condition of interest. Knowing that she is a carrier,
which increases her risk of having a child with the condi-
tion, allows for more informed reproductive planning. Often,
when a woman is found to be a carrier, her partner also re-
quires testing to provide the couple with the most accurate
risk assessment for having an affected offspring. In contrast,
if genetic testing finds that the woman is not a carrier, her risk
is substantially decreased, which would improve the chance
for a normal outcome in a future pregnancy.
Another factor that commonly increases the baseline pop-
ulation risk is maternal age. Women who are 35 years or older
at the time of delivery (i.e., advanced maternal age) are con-
sidered to have an elevated risk of having an infant with
a chromosomal abnormality, such as Down syndrome. Age
35 years at the time of delivery is designated as advanced
maternal age because at that age the risk of chromosome
abnormalities exceeds the risk of a complication from the
amniocentesis procedure used to diagnose the abnormality.
Therefore, an amniocentesis or chorionic villus sampling
procedure is routinely offered to women of advanced mater-
nal age for prenatal diagnosis of chromosome abnormalities
[17]. As with women who have risks associated with family
history and ethnic background, women with advanced mater-
nal age should receive, as part of their standard preconception
care, information about the genetic risks to a pregnancy and
the available prenatal diagnostic options. A significantly in-
creased risk for chromosome abnormalities is not associated
with advance paternal age. However, as a man reaches the age
of approximately 40 years, his risk of having an infant with
one of several autosomal dominant conditions (achondropla-
sia, Apert syndrome, Marfan syndrome, and others reviewed
in [18] and [19]), increases above the baseline population
risk [20]. This risk information should also be incorporated
into standard preconception genetic counseling and risk as-
sessments, although the advanced paternal age risk is quite
small compared to the significant risk for chromosome ab-
normalities that occurs with advanced maternal age.
The second major category of preconception genetic is-
sues is the provision of appropriate preconception care and
counseling for women with known or suspected genetic dis-
orders in order to decrease the morbidity and mortality for the
women during a future pregnancy, and to lessen the risk for
avoidable complications in the infant. As healthcare has im-
proved for infants and children with genetic disorders, many
reach adulthood and women with a variety of genetic disor-
ders are able to conceive and carry a pregnancy. However, be-
cause of their genetic condition, such women are at increased
risk for maternal complications during a pregnancy. Exam-
ples include the development of pulmonary insufficiency in
a woman with cystic fibrosis, sickle cell crisis and other
vascular complications in a woman with sickle cell disease,
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hypoglycemic seizures in women with fatty acid oxidation
disorders or glycogen storage disease type Ia, and hyperam-
monemia and encephalopathy in women with ornithine tran-
scarbamylase deficiency. For each of these and many other
genetic conditions, inadequate prenatal and postpartum care
and monitoring could lead to significant morbidity or even
death. Without doubt, women with genetic conditions need to
be aware of the added health risk during a future pregnancy,
and they should be monitored by appropriate obstetrics or
maternal-fetal medicine specialists.
Women with certain genetic metabolic conditions have an
increased risk of congenital anomalies and/or medical prob-
lems in their infants, particularly if their metabolic disorder
is not appropriately managed during a pregnancy or if they do
not follow the prescribed dietary and medication regimen. A
well- described example is maternal phenylketonuria (PKU)
embryopathy. Pregnant women with PKU or milder eleva-
tions of blood phenylalanine (hyperphenylalaninemia) who
do not follow a low-phenylalanine diet and take the medical
formula supplement will have high blood levels of pheny-
lalanine. Elevated phenylalanine levels are teratogenic and
can cause infants to have microcephaly, mental retardation,
behavioral problems, and congenital heart defects [21, 22].
Women with such genetic metabolic conditions should be
counseled and educated accordingly during preconception
care, and plans should be developed so that women with
these conditions can be in optimal metabolic control even
before becoming pregnant.
Summary
Genetic issues are too important to be ignored during pre-
conception care since they can have quite profound implica-
tions for a woman’s future pregnancies. An important rec-
ommended intervention is a complete family history assess-
ment, either though a self-assessment tool that is reviewed
by the physician, or through a questionnaire administered
by a healthcare provider. The utility and success of family
history tools in assessing risk are well established in other
medical areas [23, 24] and should be similarly effective in the
genetic assessment of risk as part of preconception care. Ge-
netic counseling information should be provided regarding
the baseline population genetic risk to a pregnancy, as well
as additional risks revealed by family history, ethnic back-
ground, and, if applicable, advanced maternal and/or paternal
ages. Appropriate carrier testing should be offered, with the
understanding that a negative carrier test result, in the case of
some DNA-based tests, does not exclude the possibility that
the individual tested is a carrier. Women with an increased
risk of having an infant with a birth defect or genetic con-
dition should be referred to a clinical genetics provider for
further counseling and information about pregnancy options.
Finally, women who themselves have a genetic condition
should receive appropriate preconception and prenatal care,
education, and medical counseling to avoid morbidity and
mortality for themselves and their future pregnancies.
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